DelveInsight’s “Non-Muscle Invasive Bladder Cancer Pipeline Insight, 2021” highlights the details around Non-Muscle Invasive Bladder Cancer. Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder.
Non-Muscle Invasive Bladder Cancer Overview
Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved. Bladder cancer is the 6th most common cancer in the United States. Nearly 81,000 people will be diagnosed in the United States with bladder cancer in 2020. Bladder cancer is more common in males than females.
Download Sample Report- Non-Muscle Invasive Bladder Cancer Pipeline Report
Non Muscle Invasive Bladder Cancer Companies
Non-Muscle Invasive Bladder Cancer Pipeline: Risk Factors
Research shows that people with certain risk factors are more likely to develop bladder cancer. These include:
• Smoking – cigarette smokers are up to three times more likely than nonsmokers to develop bladder cancer
• Older age – most people with bladder cancer are over 60, and the risk increases with age
• Being male – men are three to four times more likely than women to develop bladder cancer
Non-Muscle Invasive Bladder Cancer Pipeline: Symptoms
Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:
• Hematuria (blood in the urine) – the most common symptom, often without pain
• Frequent and urgent urination
• Pain when urine passes
• Pain in lower abdomen
• Back pain
Non Muscle Invasive Bladder Cancer Pipeline: Diagnosis
The diagnosis of bladder cancer ultimately depends on cystoscopic examination of the bladder and histological evaluation of the resected tissue although about 4% of cases will be found incidentally, usually during imaging to investigate non-urological symptoms. However, the detection rate for white light cystoscopy (WLC) can be limited (as low as 60%). Strong evidence has shown that enhanced visualization methods using (hexyl aminolevulinate (HAL)-photodynamic diagnosis (PDD) or narrow band imaging (NBI)) may improve tumor detection and early recurrence. Blue light cystoscopy (BLC) or PDD requires preoperative intravesical instillation of hexaminolevulinate (HAL), a photosensitizer that preferentially accumulates in neoplastic cells. Under blue light, red fluorescence is emitted by neoplastic cells.
Non-Muscle Invasive Bladder Cancer Treatment
The main treatments for when the cancer cells are found only in the bladder’s inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Most people with non-muscle-invasive bladder cancer have an operation called transurethral resection of bladder tumour (TURBT). This is done during a cystoscopy under a general anaesthetic. It takes 15–40 minutes, and does not involve any external cuts to the body. Immunotherapy uses substances that encourage the body’s own natural defenses (immune system) to fight disease. Bacillus Calmette-Guérin (BCG) is a vaccine that was originally used to treat tuberculosis. It can also stimulate a person’s immune system to stop or delay bladder cancer coming back or becoming invasive.
More Information– Non-Muscle Invasive Bladder Cancer Pipeline Insights
Table of content
About DelveInsight
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash
[email protected]
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/